$200m gets private Intarcia to diabetes finish line
This article was originally published in Scrip
Executive Summary
Every now and then a private biotechnology company manages to raise a substantial amount of equity before it runs out of capital – if it has impressive clinical trial data and a large market opportunity – which is what Intarcia Therapeutics did to fund completion of Phase III clinical trials for its once-yearly type 2 diabetes therapy ITCA 650.